How does the FDA evaluate HRT safety today

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, the FDA evaluates HRT safety by reviewing scientific evidence, monitoring real-world data after products reach the market, and updating warnings or requirements whenever new risks or benefits become clear. The agency focuses on dose, route, and duration to assess whether benefits outweigh risks for individual patients. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

How the FDA Reviews HRT Before Approval

According to FDA.gov, the FDA requires companies to submit rigorous research before any hormone product is approved. This includes:

• Clinical trials: Studies in humans that evaluate how well the hormone works and what side effects may appear at different doses and forms.
• Safety labs and imaging: Data on blood pressure, clotting factors, breast changes, and metabolic markers.
• Product consistency: Proof that every dose, patch, or cream delivers a stable, predictable amount of hormone.

According to FDA Drug Safety Communications, the FDA evaluates risks that have appeared in prior research — such as blood clots, stroke, and breast cancer — and requires that trials specifically look for early warning signs of these outcomes.

How the FDA Monitors HRT After Approval

According to FDA.gov, once a commercially available product is on the market, the FDA continues to monitor its safety through:

• Post-marketing reports: Doctors, patients, and pharmacists may report concerns, which the FDA continuously reviews.
• Required long-term studies: Some manufacturers must study real-world use to track rare risks.
• Label updates: If new evidence emerges, the FDA may adjust warnings, add safety information, or guide clinicians toward safer dosing practices.

Changes in HRT labeling over the years reflect ongoing scientific learning. A qualified prescriber may help interpret what updated labeling means for an individual patient's situation.

What the FDA Prioritizes When Determining Safety

• Lowest effective dose: Ensuring patients receive only the amount needed to address symptoms.
• Shortest appropriate duration: Using the minimal time needed while still supporting quality of life, as recommended by a qualified prescriber.
• Route of delivery: According to FDA-approved prescribing information, differences between pills, patches, gels, or vaginal forms may affect benefits and clotting risk differently.
• Population differences: According to the WHI, age, time since menopause, and health history may alter individual risk profiles.

According to FDA.gov, the agency's approach is shaped by decades of accumulated post-market and clinical trial data. Their stated goal is to ensure that every approved HRT option meets established standards for the populations for whom it is indicated. Patients are encouraged to discuss their individual circumstances with a qualified prescriber.